Diana Luca
University of California, Los Angeles(US)Los Angeles Medical Center(US)Ultragenyx Pharmaceutical (United States)(US)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Microscopic Colitis, Bone health and treatments, Prostate Cancer Diagnosis and Treatment, Lipoproteins and Cardiovascular Health
Most-Cited Works
- → Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial(2014)451 cited
- Antineutrophil cytoplasmic antibodies in ulcerative colitis(1995)
- → Burosumab for the Treatment of Tumor-Induced Osteomalacia(2020)169 cited
- → Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis(2015)155 cited
- → A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis(2012)150 cited
- → EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging(2013)108 cited
- → Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation